WS #16502
Eli Lilly raised its full-year guidance for the third time this year as Mounjaro and Zepbound sales soared, lifting the stock 3.3%. Bristol-Myers Squibb also beat estimates on strong Eliquis growth and raised FY guidance. NovoCure similarly beat top-line and bottom-line estimates. The healthcare sector is demonstrating pricing power and demand resilience, with weight-loss drugs and established oncology/cardiovascular franchises driving outperformance.
Pharma and Healthcare Resilience
Eli Lilly raised its full-year guidance for the third time this year as Mounjaro and Zepbound sales soared, lifting the stock 3.3%. Bristol-Myers Squibb also beat estimates on strong Eliquis growth and raised FY guidance. NovoCure similarly beat top-line and bottom-line estimates. The healthcare sector is demonstrating pricing power and demand resilience, with weight-loss drugs and established oncology/cardiovascular franchises driving outperformance.